These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20948161)

  • 1. [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
    Sugii H; Matsumura Y; Inoue A; Horigome H; Matsuzaki K; Shimizu A
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):233-41. PubMed ID: 20948161
    [No Abstract]   [Full Text] [Related]  

  • 2. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide: a once-daily human glucagon-like peptide-1 analogue.
    Aimaretti G
    J Endocrinol Invest; 2009 Sep; 32(8):701-3. PubMed ID: 19942822
    [No Abstract]   [Full Text] [Related]  

  • 4. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment evaluation of liraglutide in type 2 diabetes.
    Kela R; Davies MJ
    Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide.
    Drucker DJ; Dritselis A; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Apr; 9(4):267-8. PubMed ID: 20357801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
    Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010; 65(7-8):464-70. PubMed ID: 20857706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
    Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
    Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats.
    Brand CL; Galsgaard ED; Tornehave D; Rømer J; Gotfredsen CF; Wassermann K; Knudsen LB; Vølund A; Sturis J
    Diabetes Obes Metab; 2009 Aug; 11(8):795-803. PubMed ID: 19519868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide in the management of type 2 diabetes.
    Wajcberg E; Amarah A
    Drug Des Devel Ther; 2010 Oct; 4():279-90. PubMed ID: 21116334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
    Tanabe A; Kaneto H; Kamei S; Hirukawa H; Shimoda M; Kimura T; Obata A; Okauchi S; Tatsumi F; Kohara K; Mune T; Kaku K
    J Diabetes Complications; 2016 Aug; 30(6):1201-3. PubMed ID: 27220544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
    Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
    Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide prevents diabetes progression in prediabetic OLETF rats.
    Guo N; Sun J; Chen H; Zhang H; Zhang Z; Cai D
    Endocr J; 2013; 60(1):15-28. PubMed ID: 22986487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of liraglutide on endothelial function in patients with type 2 diabetes.
    Nandy D; Johnson C; Basu R; Joyner M; Brett J; Svendsen CB; Basu A
    Diab Vasc Dis Res; 2014 Nov; 11(6):419-30. PubMed ID: 25212693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets.
    Tudurí E; López M; Diéguez C; Nadal A; Nogueiras R
    Trends Endocrinol Metab; 2016 May; 27(5):304-318. PubMed ID: 27062006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.